3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 signaling through the induction of PIAS3

References

• Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002;96:67–202.
   PubMed Web of Science ®Google Scholar
• Gaspar A, Matos MJ, Garrido J, et al. Chromone: a valid scaffold in medicinal chemistry. Chem Rev 2014;114:4960–4992.
   PubMed Web of Science ®Google Scholar
• Keri RS, Budagumpi S, Pai RK, Balakrishna RG. Chromones as a privileged scaffold in drug discovery: a review. Eur J Med Chem 2014;78:340–374.
   PubMed Web of Science ®Google Scholar
• Nakano K, Nakayachi T, Yasumoto E, et al. Induction of apoptosis by beta-diketones in human tumor cells. Anticancer Res 2004;24:711–717.
   PubMed Web of Science ®Google Scholar
• Yadav VR, Prasad S, Gupta SC, et al. 3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IkappaBalpha kinase, leading to down-regulation of nuclear factor-kappaB (NF-kappaB)-regulated gene products and sensitization of tumor cells. J Biol Chem 2012;287:245–256.
   PubMed Web of Science ®Google Scholar
• Barath Z, Radics R, Spengler G, et al. Multidrug resistance reversal by 3-formylchromones in human colon cancer and human mdr1 gene-transfected mouse lymphoma cells. In Vivo 2006;20:645–649.
   PubMed Web of Science ®Google Scholar
• Ilamathi M, Senthilkumar S, Prabu PC, et al. Formylchromone exhibits salubrious effects against nitrosodiethylamine mediated early hepatocellular carcinogenesis in rats. Chem Biol Interact 2014;219:175–183.
   PubMed Web of Science ®Google Scholar
• Shim YS, Kim KC, Chi DY, et al. Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett 2003;13:2561–2563.
   PubMed Web of Science ®Google Scholar
• Ishihara M, Sakagami H. Re-evaluation of cytotoxicity and iron chelation activity of three beta-diketones by semiempirical molecular orbital method. In Vivo 2005;19:119–123.
   PubMed Web of Science ®Google Scholar
• Faltynek CR, Wang S, Miller D, et al. Inhibition of T lymphocyte activation by a novel p56lck tyrosine kinase inhibitor. J Enzym Inhib 1995;9:111–122.
   PubMed Web of Science ®Google Scholar
• Khan KM, Ambreen N, Hussain S, et al. Schiff bases of 3-formylchromone as thymidine phosphorylase inhibitors. Bioorg Med Chem 2009;17:2983–2988.
   PubMed Web of Science ®Google Scholar
• Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014;14:736–746.
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415–1421.
   PubMed Web of Science ®Google Scholar
• Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81–83.
   PubMed Web of Science ®Google Scholar
• Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 2002;277:45680–45687.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Sethi G, Ahn KS, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 2006;1091:151–169.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 2009;1171:59–76.
   PubMed Web of Science ®Google Scholar
• Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278:1803–1805.
   PubMed Web of Science ®Google Scholar
• Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep 2004;11:1319–1324.
   PubMed Web of Science ®Google Scholar
• Ogata Y, Osaki T, Naka T, et al. Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 2006;8:817–825.
   PubMed Web of Science ®Google Scholar
• Wible BA, Wang L, Kuryshev YA, et al. Increased K + efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3beta in prostate cancer cells. J Biol Chem 2002;277:17852–17862.
   PubMed Web of Science ®Google Scholar
• Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003;3:900–911.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim C, Kim SH, et al. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway. Cancer Lett 2015;360:280–293.
   PubMed Web of Science ®Google Scholar
• Kim SM, Kim C, Bae H, et al. 6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways. Mol Carcinog 2015;54:1132–1146.
   PubMed Web of Science ®Google Scholar
• Kim C, Kim JH, Oh EY, et al. Blockage of STAT3 signaling pathway by morusin induces apoptosis and inhibits invasion in human pancreatic tumor cells. Pancreas 2016;45:409–419.
   PubMed Web of Science ®Google Scholar
• Baek SH, Lee JH, Ko JH, et al. Ginkgetin blocks constitutive STAT3 activation and induces apoptosis through induction of SHP-1 and PTEN tyrosine phosphatases. Phytother Res 2016;30:567–576.
   PubMed Web of Science ®Google Scholar
• Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996;84:331–334.
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863–872.
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105–115.
   PubMed Web of Science ®Google Scholar
• Subramaniam A, Shanmugam MK, Perumal E, et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 2013;1835:46–60.
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798–4811.
   PubMed Web of Science ®Google Scholar
• Wen Z, Darnell JE Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 1997;25:2062–2067.
   PubMed Web of Science ®Google Scholar
• Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468–2473.
   PubMed Web of Science ®Google Scholar
• Dabir S, Kluge A, Dowlati A. The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent. Mol Cancer Res 2009;7:1854–1860.
   PubMed Web of Science ®Google Scholar
• Kluge A, Dabir S, Kern J, et al. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int J Cancer 2009;125:1728–1734.
   PubMed Web of Science ®Google Scholar
• Brantley EC, Nabors LB, Gillespie GY, et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 2008;14:4694–4704.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Kaestel CG, Eriksen KW, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 1999;13:735–738.
   PubMed Web of Science ®Google Scholar